In recent studies, the 5-year overall survival was 60%1 and the breast cancer-specific survival was 75%.2 The absence of receptors renders TNBCs unresponsive to the targeted hormonal and anti-HER2 therapies that are used in other breast cancers. Here, ERBB2 is linked to breast carcinoma.